| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
- Free radicals (DPPH, ABTS, superoxide anion): Octahydrocurcumin scavenges DPPH radical (IC₅₀ = 8.5 ± 0.3 μM), ABTS radical (IC₅₀ = 6.2 ± 0.2 μM), and inhibits superoxide anion generation (IC₅₀ = 22.4 ± 1.5 μM) [3]
- Lipid peroxidation: Octahydrocurcumin inhibits Fe²⁺-induced lipid peroxidation in rat liver microsomes (IC₅₀ = 12.3 ± 0.8 μM) [3] - NF-κB signaling pathway (p65 subunit): Octahydrocurcumin inhibits LPS-induced NF-κB p65 nuclear translocation in RAW264.7 cells (inhibits translocation, not direct binding) [2] - Inflammatory cytokines (TNF-α, IL-6): Octahydrocurcumin inhibits LPS-induced TNF-α release (IC₅₀ = 15.2 ± 1.1 μM) and IL-6 release (IC₅₀ = 18.7 ± 1.3 μM) from RAW264.7 cells [2] |
|---|---|
| ln Vitro |
1. Antioxidant activity:
- DPPH radical scavenging: Octahydrocurcumin (2-20 μM) scavenged DPPH radicals in a dose-dependent manner; IC₅₀ = 8.5 ± 0.3 μM (weaker than curcumin, IC₅₀ = 2.8 ± 0.1 μM) [3] - ABTS radical scavenging: At 10 μM, Octahydrocurcumin showed 72% ABTS radical scavenging rate; IC₅₀ = 6.2 ± 0.2 μM (curcumin IC₅₀ = 1.9 ± 0.1 μM) [3] - Superoxide anion inhibition: Octahydrocurcumin (10-50 μM) inhibited xanthine-xanthine oxidase-induced superoxide anion generation; 50 μM showed 68% inhibition rate, IC₅₀ = 22.4 ± 1.5 μM [3] - Lipid peroxidation inhibition: In rat liver microsomes, Octahydrocurcumin (5-30 μM) reduced Fe²⁺-induced malondialdehyde (MDA) production (MDA is a lipid peroxidation marker); IC₅₀ = 12.3 ± 0.8 μM [3] 2. Anti-inflammatory activity: - Inflammatory cytokine inhibition: RAW264.7 cells (murine macrophages) treated with Octahydrocurcumin (5-40 μM) + LPS (1 μg/ml) for 24 h; 20 μM Octahydrocurcumin reduced TNF-α release by 58% and IL-6 release by 52% (vs. LPS alone) [2] - NF-κB nuclear translocation inhibition: Western blot showed 20 μM Octahydrocurcumin reduced LPS-induced nuclear NF-κB p65 levels to 35% of LPS alone group; cytoplasmic p65 levels increased by 2.1-fold, confirming inhibited translocation [2] - No cytotoxicity: Octahydrocurcumin (up to 40 μM) showed no cytotoxicity to RAW264.7 cells (viability > 90%, MTT assay) [2] |
| Enzyme Assay |
1. Antioxidant activity assays:
- DPPH radical scavenging assay: - Reaction mixture (1 ml) contained 50 μM DPPH ethanol solution and Octahydrocurcumin (2-20 μM, dissolved in ethanol) [3] - Incubated at room temperature in the dark for 30 minutes; absorbance measured at 517 nm [3] - Scavenging rate (%) = [(A₀ - A₁)/A₀] × 100 (A₀ = control absorbance, A₁ = sample absorbance); IC₅₀ calculated via dose-response curve [3] - ABTS radical scavenging assay: - ABTS radical cation was generated by reacting 7 mM ABTS with 2.45 mM potassium persulfate (incubated 16 h at room temperature) [3] - Diluted ABTS solution (absorbance 0.7 ± 0.05 at 734 nm) mixed with Octahydrocurcumin (2-20 μM); incubated 10 minutes [3] - Absorbance measured at 734 nm; scavenging rate and IC₅₀ calculated as above [3] - Lipid peroxidation inhibition assay: - Rat liver microsomes (0.5 mg protein/ml) mixed with 50 μM FeSO₄, 0.1 mM ascorbic acid, and Octahydrocurcumin (5-30 μM) in 50 mM Tris-HCl buffer (pH 7.4) [3] - Incubated at 37°C for 1 h; reaction terminated by adding 10% trichloroacetic acid (TCA) [3] - MDA concentration measured by thiobarbituric acid (TBA) reaction (absorbance 532 nm); inhibition rate = [(MDA₀ - MDA₁)/MDA₀] × 100 [3] 2. NF-κB transcriptional activity assay: - RAW264.7 cells were co-transfected with NF-κB luciferase reporter plasmid and Renilla luciferase plasmid (internal control) [2] - Transfected cells pre-treated with Octahydrocurcumin (5-40 μM) for 1 h, then stimulated with LPS (1 μg/ml) for 6 h [2] - Cells lysed; luciferase activity measured using dual-luciferase assay kit; NF-κB activity = firefly luciferase/Renilla luciferase ratio [2] - Result: 20 μM Octahydrocurcumin inhibited LPS-induced NF-κB activity by 62% (vs. LPS alone) [2] |
| Cell Assay |
1. RAW264.7 macrophage inflammatory response assay:
- Cell culture: RAW264.7 cells were cultured in DMEM medium with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin (37°C, 5% CO₂) [2] - Treatment protocol: Cells (1×10⁶ cells/ml, 24-well plate) were pre-treated with Octahydrocurcumin (5-40 μM) for 1 h, then stimulated with LPS (1 μg/ml) for 24 h [2] - Inflammatory cytokine detection: Culture supernatant collected; TNF-α/IL-6 levels measured by sandwich ELISA (detection wavelength 450 nm); concentrations calculated via standard curves [2] - NF-κB p65 subcellular localization (Western blot): - Cytoplasmic and nuclear fractions extracted from treated cells using nuclear extraction kit [2] - 30 μg protein per fraction separated by SDS-PAGE, transferred to PVDF membrane, blocked with 5% non-fat milk (1 h) [2] - Membranes probed with anti-NF-κB p65 antibody (cytoplasmic/nuclear marker: α-tubulin/Lamin B1) at 4°C overnight, then secondary antibody (1 h, RT) [2] - Bands visualized with ECL; intensity quantified via densitometry [2] 2. Cell viability assay (文献[2]、[3]): - MTT assay for RAW264.7 cells: Cells (5×10³ cells/well, 96-well plate) treated with Octahydrocurcumin (5-40 μM) for 24 h; MTT (5 mg/ml, 20 μl/well) added for 4 h; formazan dissolved in DMSO; absorbance at 570 nm [2] |
| References |
|
| Additional Infomation |
According to reports, turmeric contains octahydrocurcumin, and there is relevant data available.
1. Chemical background: - Octahydrocurcumin is a hydrogenated derivative of curcumin (the main active ingredient of curcumin); its structure differs from curcumin in that the conjugated double bond in the central heptadenone chain is completely saturated, thereby improving its chemical stability and water solubility[2][3] - It is the main in vivo metabolite of curcumin, formed by the reduction of curcumin double bonds by liver enzymes (such as aldehyde reductase)[2] 2. Mechanism of action: - Antioxidant mechanism: Octahydrocurcumin scavenge free radicals (DPPH, ABTS, superoxide anion) through its phenolic hydroxyl group (electron donor), and inhibit lipid peroxidation by chelating Fe²⁺ (a pro-oxidation metal ion)[3] - Anti-inflammatory mechanism: Octahydrocurcumin inhibits LPS-induced inflammation by inhibiting NF-κB activation - blocking the nuclear translocation of the p65 subunit, thereby reducing the inflammatory response. Transcription of pro-inflammatory cytokines (TNF-α, IL-6)[2] 3. Comparison of activities: - Antioxidant activity: octahydrocurcumin has weaker free radical scavenging activity than curcumin (e.g., DPPH IC₅₀ 8.5 μM vs. curcumin 2.8 μM), but stronger lipid peroxidation inhibitory activity (curcumin IC₅₀ 18.5 μM vs. octahydrocurcumin 12.3 μM)[3] - Anti-inflammatory activity: octahydrocurcumin has about 80% of the anti-inflammatory potency of curcumin (e.g., TNF-α IC₅₀ 15.2 μM vs. curcumin 12.8 μM), but better stability in biological systems[2] |
| Molecular Formula |
C21H28O6
|
|---|---|
| Molecular Weight |
376.4434
|
| Exact Mass |
376.188
|
| CAS # |
36062-07-4
|
| PubChem CID |
11068834
|
| Appearance |
Light yellow to yellow ointment
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
623.5±55.0 °C at 760 mmHg
|
| Flash Point |
330.9±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
1.73
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
27
|
| Complexity |
370
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])(C([H])([H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H])C([H])([H])C([H])(C([H])([H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H])O[H]
|
| InChi Key |
OELMAFBLFOKZJD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H28O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h5-6,9-12,16-17,22-25H,3-4,7-8,13H2,1-2H3
|
| Chemical Name |
1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~265.65 mM)
Ethanol : ~10 mg/mL (~26.56 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (9.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (9.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.75 mg/mL (9.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6565 mL | 13.2823 mL | 26.5647 mL | |
| 5 mM | 0.5313 mL | 2.6565 mL | 5.3129 mL | |
| 10 mM | 0.2656 mL | 1.3282 mL | 2.6565 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
